The treatment of Parkinson's disease;Die therapie der Parkinson-erkrankung

Praxis

Volumn 102, Issue 25, 2013, Pages 1529-1535

  Baumann, Christian R ^a   Waldvogel, Daniel ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Dopamine; Dopamine agonists; Levodopa; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

HUMAN; PARKINSON DISEASE; PHYSIOTHERAPY; QUALITY OF LIFE; SHORT SURVEY;

AGONISTES DE LA DOPAMINE; DOPAMIN; DOPAMINAGONISTEN; DOPAMINE; DOPAMINE AGONISTS; LEVODOPA; MALADIE DE PARKINSON; PARKINSON'S DISEASE; PARKINSON-ERKRANKUNG;

ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; DOPAMINE AGONISTS; DRUG COMBINATIONS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PHYSICAL THERAPY MODALITIES;

EID: 84891925717     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a001505     Document Type: Short Survey

References (13)

1. Probst A, Bloch A, Tolnay M: New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol 2008; 15 (Suppl 1): 1-4.
2. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
3. Irwin DJ, White MT, Toledo JB, et al.: Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587-598.
4. Li F, Harmer P, Fitzgerald K, et al.: Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012; 366: 511-519.
5. Foster ER, Golden L, Duncan RP, Earhart GM: Community-Based Argentine Tango Dance Program Is Associated With Increased Activity Participation Among Individuals With Parkinson's Disease. Arch Phys Med Rehabil 2012; 94: 240-249.
6. Olanow CW, Obeso JA, Stocchi F: Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2: 382-392.
7. Olanow CW, Watkins PB: Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol 2007; 30: 287-294.
8. Stocchi F: The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009; 15 Suppl 3: 68-71.
9. Voon V, Gao J, Brezing C, et al.: Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011; 134: 1438-1446.
10. Olanow CW, Rascol O, Hauser R, et al.: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
11. Schuepbach WM, Rau J, Knudsen K, et al.: Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368: 610-622.
12. Emre M, Aarsland D, Albanese A, et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
13. Richard IH, McDermott MP, Kurlan R, et al.: A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229-1236.